Cite
HARVARD Citation
Shi, Y. et al. (2021). Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial. Cancer communications. 41 (9), pp. 889-903. [Online].